# Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

> **NCT06305702** · — · COMPLETED · sponsor: **Liaoning Cancer Hospital & Institute** · enrollment: 500 (actual)

## Conditions studied

- HER2-positive Metastatic Breast Cancer

## Interventions

- **DRUG:** inetetamab

## Key facts

- **NCT ID:** NCT06305702
- **Lead sponsor:** Liaoning Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-01-31
- **Target enrollment:** 500 (ACTUAL)
- **Last updated:** 2024-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06305702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06305702, "Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06305702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*